Evidence map›Paper›PMID 42436850›Full record

ArticleObesity pillars2026

Understanding reasons for initiation and experience with tirzepatide among individuals with obesity or overweight: Results from the PERCEPTIONS survey.

Theresa Hunter Gibble, Harriet Makin, Claire Gerber, Catherine Bottomley, Xuanyao He, Sara Pisani, Michael Shepherd, Elizabeth Collins, Angela Golden, Harold Bays

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Obesity pillars, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Theresa Hunter GibbleEli Lilly and Company, Indianapolis, IN, USA.
Harriet MakinClarivate, London, UK.
Claire GerberEli Lilly and Company, Indianapolis, IN, USA.
Catherine BottomleyClarivate, London, UK.
Xuanyao HeEli Lilly and Company, Indianapolis, IN, USA.
Sara PisaniClarivate, London, UK.
Michael ShepherdEli Lilly and Company, Indianapolis, IN, USA.
Elizabeth CollinsClarivate, London, UK.
Angela GoldenThe Obesity Society, Rockville, MD, USA.
Harold BaysMonroe Biomedical Research; Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Obesity contributes to multiple complications, increased mortality, and reduced health-related quality of life (HRQoL). Tirzepatide demonstrated sustained weight reduction and improvements in HRQoL in the SURMOUNT studies. Limited data are available regarding real-world experiences of participants initiating tirzepatide. Methods: This manuscript reports baseline data from the PERCEPTIONS survey, a real-world, observational study conducted in the US (June-November 2025). The study enrolled obesity medication (OM)-eligible adults with obesity (BMI ≥30 kg/m Results: The descriptive study included 518 participants (mean [SD] age: 46.0 [11.58] years, 78.2% female, 69.5% White, mean [SD] BMI: 38.4 [8.38] kg/m Conclusions: This real-world survey emphasized the multifaceted disease burden experienced by participants with obesity or overweight. Participants initiating tirzepatide were highly motivated to lose weight, improve their well-being, and self-confidence. Identifying common barriers to OM access will help optimize health strategies for obesity management.

Indexed as

Patient perspectivesQuality of lifeReal-world surveyTirzepatide

Identifiers

PMID42436850
PMCPMC13355407

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.